- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | BenevolentAI: Publication of the Revised Agenda for the 2024 AGM | 228 | Business Wire | Regulatory News:
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces the publication... ► Artikel lesen | |
| Mo | Proposed Changes to BenevolentAI's Board Composition | 232 | Business Wire | Regulatory News:
BenevolentAI (or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces that following extensive discussions... ► Artikel lesen | |
| 02.04. | Drug developer BenevolentAI faces founder-led board revolt | 2 | Sky News | ||
| 25.03. | BenevolentAI Announces Positive Topline Safety and Pharmacokinetic Data from the Phase Ia Clinical Study of BEN-8744 in Healthy Volunteers | 201 | Business Wire | Regulatory News:
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces positive safety... ► Artikel lesen | |
| 20.03. | BenevolentAI: Publication of 2023 Annual Report and 2024 AGM Notice | 229 | Business Wire | Regulatory News:
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces the publication... ► Artikel lesen | |
| 20.03. | BenevolentAI Appoints New Chief Technology Officer | 349 | Business Wire | BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces that the current Chief Technology... ► Artikel lesen | |
| 14.03. | BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2023 | 342 | Business Wire | Focused on delivering cutting edge AI-driven drug discovery
Regulatory News:
BenevolentAI ("BenevolentAI", "the Company" or "the Group") (Euronext Amsterdam: BAI), a leader in applying advanced... ► Artikel lesen | |
| 04.03. | BenevolentAI: Notice of Preliminary Results | 214 | Business Wire | BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, will announce its preliminary results for the year... ► Artikel lesen | |
| 24.01. | BenevolentAI taps former Bayer R&D chief to help steer the AI biotech out of choppy waters | 42 | FierceBiotech | ||
| 24.01. | BenevolentAI names pharma vet Jörg Möller as its new CEO | - | pharmaphorum | ||
| 24.01. | BenevolentAI Appoints Dr. Joerg Moeller as Chief Executive Officer | 352 | Business Wire | An accomplished R&D leader and champion of the application of AI to drug discovery
Regulatory News:
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying... ► Artikel lesen | |
| 28.12.23 | BenevolentAI: Shareholder Letter December 2023 | 384 | Business Wire | Regulatory News:
Posted to shareholders on 27 December 2023
Dear Shareholders
AI is becoming an accepted and validated approach to drug discovery and development with long term structural... ► Artikel lesen | |
| 21.09.23 | BenevolentAI: Interim Results for the Six Months Ended 30 June 2023 | 412 | Business Wire | Delivering on our strategic plan Merck collaboration, lead asset enters clinic, Knowledge tools in user testing and leadership changes
Regulatory News:
BenevolentAI (Euronext Amsterdam: BAI)... ► Artikel lesen | |
| 21.09.23 | BenevolentAI: Directorate Change | 322 | Business Wire | Regulatory News:
BenevolentAI (Euronext Amsterdam: BAI) ("BenevolentAI" or the "Company" or the "Group"), a leader in the development of advanced AI that accelerates biopharma discovery, announces... ► Artikel lesen | |
| 20.09.23 | Merck Announces Partnerships With BenevolentAI, Exscientia | 559 | AFX News | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Merck announced two new strategic drug discovery collaborations aimed at harnessing AI-driven design and discovery capabilities. The collaborations are focused... ► Artikel lesen | |
| 20.09.23 | BenevolentAI Signs Strategic Collaboration with Merck | 399 | Business Wire | Collaboration utilises BenevolentAI's end-to-end AI platform capabilities to deliver novel drug candidates, initially for three targets in oncology, neurology and immunology
BenevolentAI... ► Artikel lesen | |
| 18.09.23 | BenevolentAI Welcomes Christina Busmalis as its New Chief Revenue Officer | 603 | Business Wire | Regulatory News:
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in the development of advanced AI that accelerates biopharma discovery, today announces that... ► Artikel lesen | |
| 15.09.23 | BenevolentAI Notice of Interim Results | 393 | Business Wire | Regulatory News:
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in the development of advanced AI that accelerates biopharma discovery, will announce its interim... ► Artikel lesen | |
| 11.09.23 | BenevolentAI: Appointment of Catherine Isted, ACMA, as Chief Financial Officer | 431 | Business Wire | Regulatory News:
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in the development of advanced AI that accelerates biopharma discovery, announces the appointment... ► Artikel lesen | |
| 31.08.23 | BenevolentAI Doses First Participants in Clinical Trial of BEN-8744; Targets PDE10, an AI-derived Novel Target for the Treatment of Ulcerative Colitis | 449 | Business Wire | BEN-8744 is derived from the Benevolent PlatformTM and is a potential first-in-class PDE10 inhibitor for the treatment of Ulcerative Colitis
The topline data readout from this Phase I study... ► Artikel lesen |
Seite:
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABCELLERA BIOLOGICS | 3,654 | -0,68 % | AbCellera Reports Full Year 2023 Business Results | VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced financial results for the full year 2023. All financial information in this press release is reported in U.S.... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,475 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer | Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion's Board of DirectorsSALT LAKE... ► Artikel lesen | |
| ASCLETIS PHARMA | 0,145 | +9,02 % | Ascletis Pharma Inc.: Ascletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting | HANGZHOU and SHAOXING, China, March 10, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces the poster presentation of Phase II study final results of ASC40, a first-in-class... ► Artikel lesen | |
| VERACYTE | 17,700 | 0,00 % | Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results | SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2023.
"We closed 2023 with... ► Artikel lesen | |
| RELAY THERAPEUTICS | 6,215 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics to Participate in Upcoming Investor Conferences | ||
| ABSCI | 5,295 | 0,00 % | Absci Corporation: Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results | Initiated IND-enabling studies for ABS-101, a potential best-in-class anti-TL1A antibody Entered into collaboration with AstraZeneca for up to $247M in deal value, plus royalties Strengthened balance... ► Artikel lesen | |
| LANTERN PHARMA | 5,850 | 0,00 % | Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights | DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and... ► Artikel lesen | |
| MORPHOSYS | 67,70 | 0,00 % | Morphosys: So müssen Anleger jetzt handeln | Es sind zwei Monate vergangen seit dem Übernahmeangebot von Novartis. Die Morphosys-Aktie hat direkt einen Riesensprung auf den Übernahmepreis gemacht. Am Donnerstagvormittag hat Novartis weitere Details... ► Artikel lesen | |
| QIAGEN | 36,815 | -0,50 % | Kurs der Qiagen NV-Aktie verharrt auf Vortags-Niveau (38,605 €) | CODE Die Aktie notiert aktuell bei 38,60 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei dem Anteilsschein von Qiagen NV. Das Papier weist gegenwärtig nur einen geringen Preisanstieg... ► Artikel lesen | |
| IMMUNOVANT | 28,445 | 0,00 % | Immunovant, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| VERA THERAPEUTICS | 40,020 | 0,00 % | Aktien New York Ausblick: Vor dem Start in die Berichtssaison stabil erwartet | NEW YORK (dpa-AFX) - Nach einem schwachen Handelsverlauf am Vortag dürften sich die US-Börsen am Donnerstag stabilisieren. Am Mittwoch hatte eine überraschend hohe Inflation im Monat März die Hoffnungen... ► Artikel lesen | |
| EVOTEC | 13,010 | -1,51 % | Evotec: Es könnte noch eine umgekehrte SKS werden, aber … | Mit -7,16 Prozent wurde die Evotec-Aktie am Mittwoch zum größten Verlierer in MDAX und TecDAX. Danach sah es zunächst gar nicht aus, aber am frühen Nachmittag kam es zu zwei markanten Verkaufsschüben... ► Artikel lesen | |
| BIONTECH | 80,20 | -0,43 % | BioNTech: Alle Aktien verkaufen oder? | Richtig leiden müssen heute BioNTech-Aktionäre. In den Büchern steht für den Kurs nämlich ein Minus von rund zwei Prozent. Nur noch 81,45 EUR müssen nach diesem Abschlag für ein Wertpapier hingelegt... ► Artikel lesen | |
| NUVALENT | 64,17 | 0,00 % | US 3M, J&J, Nuvalent | ||
| TSCAN THERAPEUTICS | 6,750 | 0,00 % | TScan Therapeutics, Inc.: TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities | Over 40 solid tumor patients have completed all biomarker testing in the screening protocol; ~60% of these patients qualify for at least one TCR-T in the ImmunoBank and ~30% are eligible for multiplex... ► Artikel lesen |
BENEVOLENTAI gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,630 Euro und damit -1,25 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
